Company: NCEL
Filing Date: 2025-11-20
Form Type: 6-K
Source: 0001213900-25-113139
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-11-20
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2025 (Report No. 5)

Commission file number: 001-39957

NEWCELX LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒
Form 40-F ☐

CONTENTS</div>

In connection with the closing
of the merger (the “Merger”) between NewCelX Ltd. (the “Company”) (formerly known as NLS Pharmaceutics Ltd.) and
Kadimastem Ltd. (“Kadimastem”), and as part of the post-merger integration, Kadimastem’s independent registered public
account firm, Kost Forrer Gabbay & Kasierer, a member Ernst & Young (“EY”), was appointed on November 20, 2025, following
Audit Committee approval, as the Company’s independent registered public accounting firm for the fiscal year ending December 31,
2025, effective immediately.

Previously, on November 17,
2025, following the approval of the Audit Committee, the Company dismissed CBIZ CPAs, P.C. (“CBIZ CPAs”), the Company’s
independent registered public accounting firm. As previously disclosed in the Company’s Report on Form 6-K furnished to the SEC
on September 19, 2025, Marcum LLP (“Marcum”) had served as the Company’s independent registered public accounting firm
for the fiscal year ended December 31, 2024. On September 17, 2025, in connection with the acquisition by CBIZ CPAs of Marcum’s
attestation business, CBIZ CPAs replaced Marcum as the Company’s independent registered public accounting firm. CBIZ CPAs did not
issue an audit report on the Company’s financial statements.

For the period September 17,
2025 through November 17, 2025, there were (i) no “disagreements